Problems in Pharmacology: Clinical Trials and Molecular Markers

This week’s post follows on from something I touched on last week: the issues in the drug design process. Drug design tends to be stem either from mimicry of molecules the chemist knows that the drug target already interacts with (such as a substrate that binds to an enzyme) or from knowledge of the potential’s … Read moreProblems in Pharmacology: Clinical Trials and Molecular Markers